Recent Price Movement and Market Context
On 20 Jan 2026, Rossari Biotech’s share price fell by 1.51%, underperforming the Sensex which declined by 1.04% on the same day. Despite this, the stock marginally outperformed its sector by 1.27% today. The stock has been on a consistent decline for six consecutive trading days, losing 7.78% in that span. This recent slump culminated in the stock hitting Rs.519.4, its lowest level ever recorded.
The stock is currently trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling a persistent bearish trend. This technical positioning underscores the stock’s weak momentum relative to its historical price levels.
Comparative Performance Against Benchmarks
Rossari Biotech’s performance over various time frames has been notably weaker than the broader market indices. Over the past one year, the stock has declined by 37.20%, while the Sensex has gained 6.89%. Year-to-date, the stock is down 11.34%, compared to the Sensex’s 3.33% decline. Over three and five years, the stock has lost 27.68% and 41.42% respectively, whereas the Sensex has appreciated by 35.90% and 65.45% in the same periods. The stock’s 10-year return stands at 0.00%, starkly contrasting with the Sensex’s 242.38% gain.
This consistent underperformance extends to the BSE500 index, with Rossari Biotech generating negative returns in each of the last three annual periods, highlighting a prolonged period of relative weakness.
Fast mover alert! This Large Cap from Automobiles - Passeenger just qualified for our Momentum list with stellar technical indicators. Strike while the iron is hot!
- - Recent Momentum qualifier
- - Stellar technical indicators
- - Large Cap fast mover
Financial Metrics and Credit Profile
Rossari Biotech’s financial indicators reveal areas of concern. The company’s operating profit to interest ratio for the quarter stands at a low 8.98 times, indicating tighter coverage of interest expenses. The return on capital employed (ROCE) for the half-year period is at 12.97%, the lowest recorded, reflecting subdued capital efficiency. Meanwhile, the debt-to-equity ratio has increased to 0.28 times, the highest level for the company, signalling a modest rise in leverage.
Despite this, the company maintains a relatively low average debt-to-equity ratio of 0.07 times, which remains conservative compared to many peers in the specialty chemicals sector. The enterprise value to capital employed ratio is 2.1, suggesting an attractive valuation relative to the capital base.
Profitability and Valuation Considerations
Over the past year, Rossari Biotech’s profits have increased marginally by 1.2%, even as the stock price declined sharply. This divergence is reflected in a high price/earnings to growth (PEG) ratio of 18.2, indicating that the stock’s valuation is not fully aligned with its earnings growth trajectory.
The company’s Mojo Score currently stands at 36.0, with a Mojo Grade of Sell, downgraded from Hold on 8 Dec 2025. The market capitalisation grade is 3, reflecting a mid-tier valuation status within its sector.
Shareholding and Institutional Interest
Institutional investors hold a significant 20.59% stake in Rossari Biotech, suggesting that entities with greater analytical resources maintain exposure to the stock. This level of institutional holding is notable given the stock’s recent performance and valuation metrics.
Holding Rossari Biotech Ltd from Specialty Chemicals? See if there's a smarter choice! SwitchER compares it with peers and suggests superior options across market caps and sectors!
- - Peer comparison ready
- - Superior options identified
- - Cross market-cap analysis
Summary of Performance Trends
Rossari Biotech’s share price has demonstrated a persistent downtrend across multiple time horizons, with returns significantly lagging benchmark indices. The stock’s technical indicators, including its position below all major moving averages, reinforce the subdued momentum. Financial ratios point to a cautious credit profile with modest leverage and declining capital efficiency.
While the company’s profits have shown slight growth, this has not translated into positive returns for shareholders, as reflected in the elevated PEG ratio. The downgrade in Mojo Grade to Sell further highlights the market’s reassessment of the stock’s outlook based on recent results and financial metrics.
Overall, the stock’s new all-time low price of Rs.519.4 marks a critical point in its valuation history, underscoring the challenges faced by Rossari Biotech within the specialty chemicals sector.
Unlock special upgrade rates for a limited period. Start Saving Now →
